News
Background: Nintedanib, an oral inhibitor of VEGF-FGF-PDGF receptors, has been shown to prolong progression-free survival (PFS) when added to adjuvant chemotherapy after primary surgery (duBois A, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback